

Financial statements of

Ovarian Cancer Canada

March 31, 2017

Ovarian Cancer Canada

March 31, 2017

Table of contents

Independent Auditor’s Report 1-2

Statement of financial position 3

Statement of operations 4

Statement of changes in fund balances 5

Statement of cash flows 6

Notes to the financial statements 7-11

Independent Auditor's Report

To the Board of Directors of
Ovarian Cancer Canada

We have audited the accompanying financial statements of Ovarian Cancer Canada which comprise the statement of financial position as at March 31, 2017, the statements of operations, changes in fund balances and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis for Qualified Opinion

In common with many not-for-profit organizations, Ovarian Cancer Canada derives the majority of its revenues from the general public in the form of donations and events revenue, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our verification of these revenues was limited to the amounts recorded in the records of Ovarian Cancer Canada, and we were not able to determine whether any adjustments might be necessary to donations and events revenue, excess (deficiency) of revenues over expenses, and cash flow from operations for the years ended March 31, 2017 and March 31, 2016, current assets as at March 31, 2017 and March 31, 2016 and fund balances as at April 1 and March 31 for both the 2017 and 2016 years. Our audit opinion for the year ended March 31, 2016 was modified accordingly because of the possible effects of this limitation in scope.

Qualified Opinion

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements present fairly, in all material respects, the financial position of Ovarian Cancer Canada as at March 31, 2017 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Deloitte LLP

Chartered Professional Accountants
Licensed Public Accountants
June 19, 2017

Ovarian Cancer Canada

Statement of financial position as at March 31, 2017

	2017	2016
	\$	\$
Assets		
Current assets		
Cash	159,787	182,904
Investments (Note 3)	1,712,008	1,301,688
Accounts receivable	176,953	138,542
Prepaid expenses	30,649	21,995
	2,079,397	1,645,129
Capital assets (Note 4)	1,631	2,608
Other long-term asset (Note 5)	4,861	2,843
	2,085,889	1,650,580
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities (Note 12)	222,120	193,608
Deferred grants and donations (Note 6)	348,631	222,264
	570,751	415,872
Fund balances		
General	1,513,507	1,232,100
Invested in capital assets	1,631	2,608
	1,515,138	1,234,708
	2,085,889	1,650,580

Approved on behalf of Board

 _____ Director

 _____ Director

Ovarian Cancer Canada

Statement of operations year ended March 31, 2017

	2017	2016
	\$	\$
Revenue		
Foundation grant	68,560	55,710
Donations		
Individuals	452,552	394,082
Corporate	547,811	430,490
Bequests	190,176	90,262
Events	2,997,466	2,845,305
Other	228,904	102,495
Investment income (Note 7)	11,197	12,296
	4,496,666	3,930,640
Expenses		
Administrative	234,944	231,196
Awareness and education	1,402,313	1,383,115
Fundraising	1,412,768	1,275,613
Research	422,230	380,009
Support	743,981	784,762
	4,216,236	4,054,695
Excess (deficiency) of revenue over expenses for the year	280,430	(124,055)

The accompanying notes to the financial statements are an integral part of this financial statement.

Ovarian Cancer Canada

Statement of changes in fund balances year ended March 31, 2017

			2017	2016
	General fund	Invested in capital assets	Total	Total
	\$	\$	\$	\$
Fund balances, beginning of year	1,232,100	2,608	1,234,708	1,358,763
Excess (deficiency) of revenue over expenses	281,407	(977)	280,430	(124,055)
Fund balances, end of year	1,513,507	1,631	1,515,138	1,234,708

The accompanying notes to the financial statements are an integral part of this financial statement.

Ovarian Cancer Canada

Statement of cash flows year ended March 31, 2017

	2017	2016
	\$	\$
Operating activities		
Cash from operations		
Excess (deficiency) of revenue over expenses for the year	280,430	(124,055)
Items not affecting cash		
Amortization of capital assets	977	2,172
	281,407	(121,883)
Changes in non-cash working capital components		
Accounts receivable	(38,411)	(50,201)
Prepaid expenses	(8,654)	701
Accounts payable and accrued liabilities	28,512	(132,215)
Deferred grants and donations	126,367	61,572
	389,221	(242,026)
Investing activities		
Purchase of investments	(1,210,320)	(1,412,239)
Increase in other long-term asset	(2,018)	(1,793)
Purchase of capital assets	-	(1,544)
Proceeds from disposal of investments	800,000	1,700,000
	(412,338)	284,424
Decrease in cash	(23,117)	42,398
Cash, beginning of year	182,904	140,506
Cash, end of year	159,787	182,904

The accompanying notes to the financial statements are an integral part of this financial statement.

Ovarian Cancer Canada

Notes to the financial statements

March 31, 2017

1. Purpose of organization

Ovarian Cancer Canada (“OCC”), formerly National Ovarian Cancer Association (the “Association”), was founded in 1997 and is dedicated to overcoming ovarian cancer and providing leadership by:

- supporting women and their families living with the disease;
- raising awareness by providing educational programs and materials to women living with ovarian cancer, the general public, and health care professionals; and
- funding research to develop reliable early detection techniques, improved treatments and, ultimately a cure.

The Association was incorporated on January 7, 1998 under the Canada Corporations Act as a Not-for-Profit Organization under the name of the Corinne Boyer Fund to continue this mission. The Association was granted registered charity status under the Income Tax Act (Canada) on March 26, 1999, effective August 1, 1998.

Effective February 28, 2007, the Association and the former Ovarian Cancer Canada (“the former OCC”) joined together to form one organization and the assets, liabilities and obligations of the former OCC were transferred to, and assumed by, the Association.

The former OCC was dissolved on October 29, 2007 and the Association subsequently changed its name to Ovarian Cancer Canada.

OCC was continued under the Canada Not-for-Profit Corporations Act on May 12, 2014.

2. Summary of significant accounting policies

Basis of presentation

The financial statements of OCC are the representations of management prepared in accordance with Canadian accounting standards for not-for-profit organizations set out in Part III of the Chartered Professional Accountants (CPA) Handbook. The significant accounting policies adopted by OCC are as follows:

Revenue recognition

OCC follows the deferral method of accounting for restricted contributions. Restricted grants and donations are recognized as revenue in the year in which the related expenses are incurred. Unrestricted grants and donations are recognized as revenue when received, or receivable, if the amount to be received can be reasonably estimated and collection is reasonably assured.

Contributed services

The operations of OCC are dependent on the services of many volunteers. The value of contributed services is not recognized in these financial statements.

Capital assets

Capital assets are stated at cost, less accumulated amortization. Amortization of computer and office equipment is provided on the straight-line basis over four years.

Financial instruments

OCC has elected to value its financial instruments as follows:

<u>Asset/liability</u>	<u>Category</u>
Cash	Fair value
Investments	Fair value
Accounts receivable	Amortized cost
Accounts payable and accrued liabilities	Amortized cost

Ovarian Cancer Canada

Notes to the financial statements

March 31, 2017

2. Summary of significant accounting policies (continued)

Use of estimates

The preparation of financial statements in accordance with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the statement of financial position and the reported amounts of revenue and expenses for the year then ended. Actual results may differ from such estimates. The balances which require estimates are certain accrued liabilities, deferred revenue, and amortization, which is based on the estimated useful lives of capital assets.

3. Investments

Investments consist of high interest savings accounts where cost approximates fair value.

4. Capital assets

			2017	2016
	Cost	Accumulated amortization	Net book value	Net book value
	\$	\$	\$	\$
Computer equipment	5,171	4,883	288	439
Office equipment	21,124	19,781	1,343	2,169
	26,295	24,664	1,631	2,608

5. Other long-term asset

OCC received a donation of a life insurance policy in which OCC is the owner and at the same time, the beneficiary. The policy requires that OCC pay the annual premiums of the policy and OCC intends to continue to cover the premium costs. No revenue has been recorded in the Statement of operations in respect of this donation at this time. The premiums paid on the policy are recorded as a long-term asset in the Statement of financial position. In the event OCC ceases to make premium payments on the policy, the investment less any cash surrender value received will be expensed. At the time the benefits of the policy are received by OCC, donation revenue will be recognized as the difference between the cumulative premiums paid and the payment received on the policy. As at March 31, 2017 the balance of this long-term asset is \$4,861 (2016 - \$2,843).

6. Deferred grants and donations

Deferred grants and donations consists of unspent restricted contributions and other deferred revenue. Changes in the balances of deferred grants and donations and other deferred revenue are as follows:

	2017	2016
	\$	\$
Balance, beginning of year	222,264	160,692
Add: amount received during the year	767,976	610,458
Less: amount recognized as revenue during the year	641,609	548,886
Balance, end of year	348,631	222,264

Ovarian Cancer Canada

Notes to the financial statements

March 31, 2017

6. Deferred grants and donations (continued)

The balance is comprised of the following:

	2017	2016
	\$	\$
Externally restricted grants and donations	233,343	183,134
Other deferred revenue	115,288	39,130
	348,631	222,264

7. Investment income

Investment income earned is reported as follows:

	2017	2016
	\$	\$
Income earned on unrestricted resources	11,197	12,296

8. Commitments

Leases

Future minimum annual lease commitments on office premises and equipment leases, which expire up to 2021, are as follows:

	\$
2018	272,298
2019	218,237
2020	195,672
2021	180,682
	866,889

Research commitment

OCC has committed to pay two grants of \$60,000 each, totaling \$120,000, to a research organization in the year ending March 31, 2018. The OCC contribution will be matched by the research organization.

9. Additional information to comply with the disclosure requirements of the Charitable Fundraising Act of Alberta

Remuneration paid to employees for activities involving fundraising, together with associated employee benefits and statutory payroll costs, amounted to \$416,969 (2016 - \$535,020).

Ovarian Cancer Canada

Notes to the financial statements

March 31, 2017

10. Guarantees

In the normal course of business, OCC enters into agreements that meet the definition of a guarantee.

Indemnity has been provided to all directors and officers of OCC, subject to certain restrictions. OCC has purchased directors' and officers' liability insurance to mitigate the cost of any potential future legal actions. Further, in the normal course of business, OCC has entered into agreements that include indemnities in favour of third parties, such as engagement letters with advisors and consultants, leasing contracts and rental agreements. Historically, OCC has not incurred any costs as a result of such suits, actions or agreements. The maximum amount of any potential future payment cannot be reasonably estimated and hence no amount has been recorded in the financial statements.

11. Allocation of expenses

Staff costs

OCC allocates staff costs based on management's estimate of the amount of time required to fulfill the duties of each position. Total salary and benefits subject to allocation amount to \$1,949,227 (2016 - \$2,079,990) and are allocated on the Statement of operations as follows:

	2017	2016
	%	%
Administrative	19	15
Awareness and education	34	33
Fundraising	21	26
Research	4	5
Support	22	21
	100	100

Administrative expenses

The major components of administrative expenses subject to allocation are:

	2017	2016
	\$	\$
Common expenses		
Occupancy	262,825	261,740
General and office	112,026	108,003
Accounting staff cost	190,179	146,471
Professional and consulting	57,675	60,377
Total common expenses before reallocation	622,705	576,591

Ovarian Cancer Canada

Notes to the financial statements

March 31, 2017

11. Allocation of expenses (continued)

Common administrative expenses

Common expenses are allocated based on management's estimate of the proportion of benefit received by each of the functions. Common expenses are allocated as follows:

	2017		2016	
	\$	%	\$	%
Administrative	63,197	10	57,659	10
Awareness and education	186,503	30	172,977	30
Fundraising	93,251	15	86,489	15
Research	93,251	15	86,489	15
Support	186,503	30	172,977	30
	622,705	100	576,591	100

12. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities includes \$22,905 (2016 - \$19,802) relating to government remittances.